We developed a biomimetic triple-antibody-immobilized magnetic fucoidan nanomedicine as a multifunctional artificial antigen presenting cell, which possessed the ability to not only inhibit immune checkpoint but activate tumor infiltrated T cells. of Bridging sites with tunable density on the nanoplatform was designed, allowing the antibodies to be well-distributed on the surface for mimicking immune cells. In contrast to the
complex cell expansion process using microbeads in adaptive cell
therapy, the nanoplatform can be i.v. administrated to cut the course of
therapy from several weeks to days. With the development of the
platform technology, an artificial immune system family can be built to
pave the way for personalized immunotherapy.
